STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Clinical trials for STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy hopes to beat rare skin cancer
Disease control Recruiting nowThis study tests whether combining two treatments—extracorporeal photopheresis (a light-based blood treatment) and mogamulizumab (a targeted antibody)—can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advanced stages of the disea…
Matched conditions: STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
New study aims to decode drug rash vs. disease worsening in rare skin cancers
Knowledge-focused Recruiting nowThis study looks at a common side effect—skin rash—caused by the drug mogamulizumab in people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. The rash can look like the cancer itself, which may lead doctors to stop treatment too early. Researchers will…
Matched conditions: STAGE IIA MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC